OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment
OrthoSpineNews
JANUARY 29, 2025
. “The anatomical design of the implant restores the normal stabilization and cushioning functions of the meniscus to relieve symptoms and preserve knee joint health.” ” OrthoPreserve hopes to launch their Pilot clinical trial in 2026, while aiming for potential FDA approval by 2029. About OrthoPreserve, Inc.
Let's personalize your content